Table 4.
Type J 2.5 g | Type J 5 g | Type J 10 g | Conv. CP 10 g | Placebo | |
---|---|---|---|---|---|
WOMAC | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0002* | — | — | — | — |
Type J 10 g | 0.0001* | 0.0500 | — | — | — |
Conv. CP 10 g | 0.7652 | 0.0138* | 0.0006* | — | — |
Placebo | 0.0001* | 0.0000* | 0.0001* | 0.0001* | — |
Pain Scale | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0001* | — | — | — | — |
Type J 10 g | 0.0001* | 0.4190 | — | — | — |
Conv. CP 10 g | 0.9783 | 0.0004* | 0.0001* | — | — |
Placebo | 0.0020* | 0.0000* | 0.0000* | 0.0010* | — |
QoL | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0131* | — | — | — | — |
Type J 10 g | 0.0001* | 0.0011* | — | — | — |
Conv. CP 10 g | 0.7111 | 0.0586 | 0.0001* | — | — |
Placebo | 0.0000* | 0.0000* | 0.0000* | 0.0000* | — |
PICS | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0001* | — | — | — | — |
Type J 10 g | 0.0001* | 0.1263 | — | — | — |
Conv. CP 10 g | 1.0000 | 0.0001* | 0.0001* | — | — |
Placebo | 0.0000* | 0.0000* | 0.0000* | 0.0000* | — |
CTX-II | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0001* | — | — | — | — |
Type J 10 g | 0.0001* | 0.0001* | — | — | — |
Conv. CP 10 g | 0.0001* | 0.0001* | 0.0001* | — | — |
Placebo | 0.0001* | 0.0001* | 0.0001* | 0.0001* | — |
MOAKS | |||||
Type J 2.5 g | — | — | — | — | — |
Type J 5 g | 0.0001* | — | — | — | — |
Type J 10 g | 0.0001* | 0.0001* | — | — | — |
Conv. CP 10 g | 0.6481 | 0.0001* | 0.0001* | — | — |
Placebo | 0.0001* | 0.0001* | 0.0001* | 0.0001* | — |
CP = collagen peptides; WOMAC = Western Ontario McMaster Universities Arthritis Index; PICS = Physician’s Impression of change Score; CTX-II = C-terminal telopeptides of collagen type II; MOAKS = Magnetic Resonance Imaging Osteoarthritis Knee Score; QoL = Quality of Life.
Significant values.